Results 61 to 70 of about 14,308 (181)

Re-treatment of previous non-responders and relapsers to interferon plus ribavirin with peginterferon alfa-2a (40KD), ribavirin ± amantadine in patients with chronic hepatitis C: randomized multicentre clinical trial

Annals of Hepatology, 2012
Introduction. A large number of patients with chronic hepatitis C have not been cured with interferon-based therapy. Therefore, we evaluated the efficacy of amantadine combined with the standard of care (pegylated interferon plus ribavirin) in patients ...
Mario G. Pessôa, Hugo Cheinquer, Paulo R.L. Almeida, Giovanni F. Silva, Maria Patelli J.S. Lima, Raymundo Paraná, Marco A. Lacerda, Edison R. Parise, José R.B. Pernambuco, Suelene S. Pedrosa, Rosângela Teixeira, Hoel Sette, Jr, Fernando Tatsch   +12 more
doaj   +1 more source

Acute hepatitis C treatment

Annals of Hepatology, 2010
There are no well established treatment guidelines about acute hepatitis C (AHC), leaving physicians to make several challenging decisions, such whether to treat, when to treat and what treatment regimens to use.
Paulo Roberto Lerias de Almeida
doaj   +1 more source

Chronic hepatitis b with type I diabetes mellitus and autoimmune thyroiditis development during interferon alpha therapy

Journal of Infection in Developing Countries, 2011
Interferon alpha is a molecule frequently used in the treatment of chronic hepatitis B, C, and D, with immunomodulatory and antiviral activity. It is also used in some cancer types. It has been widely claimed that interferon alpha triggers autoimmunity,
Sukran Kose, Ayhan Gozaydin, Gulgun Akkoclu, Gulfem Ece   +3 more
doaj   +1 more source

Predictive value of interferon-lambda gene polymorphisms for treatment response in chronic hepatitis C.

PLoS ONE, 2014
BackgroundIL28B gene polymorphism is the best baseline predictor of response to interferon alfa-based antiviral therapies in chronic hepatitis C. Recently, a new IFN-L4 polymorphism was identified as first potential functional variant for induction of ...
Simone Susser, Eva Herrmann, Christian Lange, Nabila Hamdi, Tobias Müller, Thomas Berg, Dany Perner, Stefan Zeuzem, Christoph Sarrazin   +8 more
doaj   +1 more source

Comparison of peginterferon alfa-2a and alfa-2b for treatment of patients with chronic hepatitis C:a retrospective study using the Japanese Interferon Database

Drug Design, Development and Therapy, 2014
Izumi Sato,1 Takuro Shimbo,2 Yohei Kawasaki,3 Naohiko Masaki41Department of Clinical Study and Informatics, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan; 2Ohta Nishinouchi Hospital, Fukushima, Japan ...
Sato I, Shimbo T, Kawasaki Y, Masaki N
doaj  

RELATIONSHIP BETWEEN FIBROSIS SCORE AND RESPONSE TO INTERFERON ALFA & RIBAVIRIN COMBINATION THERAPY IN CHRONIC HCV INFECTION

Pakistan Armed Forces Medical Journal, 2009
Objective: To compare the response to Interferon Alfa (IFN) and Ribavirin (RBV) combination therapy in patients of chronic HCV infection with fibrosis stage 1 (F1) & stage 2 (F2) with fibrosis stage 3 (F3) & stage 4 (F4).
Nauman Kashif, Shahzad Saeed, Tariq Mahmood Ahmad   +2 more
doaj   +2 more sources

Tratamiento del linfoma cutáneo de células T con bexaroteno a dosis bajas en combinación con fototerapia o interferon alfa: comunicación de ocho casos tratados en el Hospital Edgardo Rebagliati Martins, 2003-2007, Lima, Perú

Acta Médica Peruana, 2018
Introducción: bexaroteno es un rexinoide aprobado en el tratamiento de estadios tempranos y avanzados del linfoma cutáneo de células T (LCCT). Caso Clínico: el presente reporte de casos mostramos los resultados del empleo de bexaroteno en dosis bajas ...
Brady Beltrán Gárate, Antonio Paredes Arcos, Celia Moisés Alfaro, Gadwin Sanchez Félix, Luis Riva Gonzales, Fernando Hurtado de Mendoza, Esther Cotrina Montenegro, Renzo Salas Rojas   +7 more
doaj  

Zidovudine and Interferon Alfa based regimens for the treatment of adult T-cell leukemia/lymphoma (ATLL): a systematic review and meta-analysis. [PDF]

Virol J, 2023
Shafiee A, Seighali N, Taherzadeh-Ghahfarokhi N, Mardi S, Shojaeian S, Shadabi S, Hasani M, Haghi S, Mozhgani SH.   +8 more
europepmc   +1 more source

Efectividad del interferón peguilado alfa 2a más ribavirina para la hepatitis crónica C en la práctica

Acta Gastroenterológica Latinoamericana, 2010
Antecedentes. En la actualidad el tratamiento estándar y consensuado de la infección crónica por el virus de la hepatitis C se basa en la combinación de dos fármacos: interferón peguilado y ribavirina.
Nelia Hernández, Germán Mescia, Carmen Pollio, Gabriela Robaina, Laura Quintana, Carla Bianchi   +5 more
doaj  

Pharmacists' role in multidisciplinary diagnosis and treatment in adverse reactions: A case report of interferon alfa-2b induced severe lupus. [PDF]

Medicine (Baltimore), 2022
Chen H, Qiu X, Wang J, Wei H.
europepmc   +1 more source